This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
20 - 22 October, 2025
Presented in Japan Standard TimeThe Westin Miyako Kyoto

Delivered as a Hybrid Event

Dr. Ben Hatano, MD, PhD
Head of Clinical Science at Genmab
Speaker

Profile

Dr. Ben Hatano, MD, PhD, MBA, is an accomplished oncology and immunology expert with extensive experience in clinical development and medical affairs. With a PhD in Surgical Pathology from Fukuoka University and an MBA from the Kenichi Ohmae Graduate School of Business, Dr. Hatano excels in aligning strategic plans with global development strategies.

Currently, as the Head of Clinical Science at Genmab in Japan, he leads groundbreaking oncology treatments, enhancing team capabilities and driving successful project execution. Previously, at BMS, Celgene and Novartis, Dr. Hatano led numerous clinical trials and facilitated approvals of key immunology and oncology therapies.

With a postdoctoral fellowship at Harvard School of Public Health, Dr. Hatano's academic tenure included advanced research in metabolic diseases. Recognized for his leadership, he has contributed to over 40 peer-reviewed publications and high-impact clinical protocols, shaping the future of medical treatment through innovation and patient care in the pharmaceutical industry.

Agenda Sessions

  • Development Overview of Bispecific DuoBody®-PD-L1×4-1BB (Acasunlimab): Next Generation Cancer Immunotherapy

    11:15